No current GLP-1 label lists inflammation as an approved use, so prescribing one for it would be off-label. STEP 1, 2 and 3 (Semaglutide 2.4 mg): C-reactive protein, a blood marker of inflammation, fell 44%, 39% and 48% more than on placebo in the three trials at 68 weeks, in parallel with weight loss. This is a marker in the blood: it does not show that a person feels or fares better. ClinicalTrials.gov lists 23 trials of these medicines on it: 2 with posted results and 3 recruiting now.
Read from the registry and PubMed every day. The newest update here is Nov 4, 2026.
Each read in the paper's abstract on Nov 6, 2026. Trials differ in who took part and how long they ran.
Semaglutide 2.4 mg · Mixed · Placebo-controlled randomized trial
C-reactive protein, a blood marker of inflammation, fell 44%, 39% and 48% more than on placebo in the three trials at 68 weeks, in parallel with weight loss. This is a marker in the blood: it does not show that a person feels or fares better.
GLP-1s and tirzepatide · Mixed · Meta-analysis
In type 2 diabetes, GLP-1s lowered C-reactive protein across 27 studies. Their effects on two other inflammation markers, IL-6 and TNF-alpha, were not statistically significant. Two tirzepatide trials showed a significant fall in IL-6 and a non-significant trend towards lower C-reactive protein.
A trial counts when the registry's conditions or title name this, and some study a related question, such as insulin sensitivity in people with the condition. A registered trial shows a question being asked, not that the answer is yes.
| Medicine | Trials | Posted results | Recruiting |
|---|---|---|---|
| Semaglutide | 8 | 0 | 2 |
| Liraglutide | 7 | 1 | 0 |
| Exenatide | 4 | 1 | 0 |
| Tirzepatide | 4 | 0 | 1 |
Latest phases and largest trials first. Each result is the first primary outcome as its sponsor posted it to the registry, which is not peer review.
| Trial | Medicine | Phase | People | Result |
|---|---|---|---|---|
| NCT03260881Liraglutide Effects on Epicardial Fat Inflammatory Genes | Liraglutide | Phase 4 | 38 | On ClinicalTrials.gov |
| NCT01951651Effect of Exenatide on Liver and Heart Fat and Inflammation | Exenatide | Phase 4 | 24 | On ClinicalTrials.gov |
The registry page names each site and who can enroll. Ask your clinician before joining one.
| Trial | Medicine | Phase | Expected to finish |
|---|---|---|---|
| GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM | Semaglutide | Phase 4 | Mar 8, 2027 |
| Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis | Semaglutide | Phase 4 | Feb 28, 2027 |
| Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease | Tirzepatide | Phase 2 | Aug 2028 |
Written from each source's own record as it changes. Every change on GLPcompare
STEP 1, 2 and 3 (Semaglutide 2.4 mg): C-reactive protein, a blood marker of inflammation, fell 44%, 39% and 48% more than on placebo in the three trials at 68 weeks, in parallel with weight loss. This is a marker in the blood: it does not show that a person feels or fares better.
Not in any current label we read. A prescriber can still use a medicine off-label, but insurance often limits coverage to approved uses, so ask your plan.
Semaglutide, with 8 registered trials on it, then Liraglutide with 7. More trials do not mean better results: read what each posted.
3 trials are recruiting on ClinicalTrials.gov now, listed below with their registry pages, which name each site and who can enroll.